Apollo Funds Close €3 Billion Bayer Capital Solution as KKR Joins Investment

Apollo-managed funds and affiliates have closed a €3 billion capital solution for Bayer, with KKR joining the investment as a significant minority participant. The financing puts new equity into a newly created entity that holds Bayer’s long-acting reversible contraceptives business, while leaving Bayer with a majority stake and full operational control.

The closing completes a financing first announced in July and adds KKR to a structure that was initially presented as an Apollo investment. Neither Apollo nor Bayer disclosed how much of the €3 billion is being provided by KKR, the exact ownership percentages held by the two investment firms, or any change to the total amount of capital raised.

In its September 16 closing announcement, Apollo said there are no changes to the LARC strategy as a result of the investment. Bayer continues to control the business operationally, making the financing materially different from a sale of the unit or a transfer of control to the private-capital investors.

KKR joins without changing Bayer’s control of the LARC business

The structure centers on Bayer’s long-acting reversible contraceptives operations. Apollo and KKR have invested equity into the entity that holds those activities, but Bayer remains the majority owner. The companies have not described KKR’s participation beyond calling it significant and minority in size, so the public information does not support assigning a specific stake or euro amount to KKR.

Bayer said when the financing was announced in July that the LARC activities would continue to be part of its Pharmaceuticals Division’s core business and that the new entity would remain fully consolidated in Bayer’s group financial statements. The company also said there would be no change to the LARC strategy or business activities because of the financing. Apollo’s closing release repeats the point that the operating strategy remains unchanged.

That distinction is important to the economics of the arrangement. Bayer has raised a large amount of equity capital against a business it continues to control, rather than selling the business outright. Apollo described the financing as part of its High Grade Capital Solutions activity, which is designed to provide large companies with tailored capital structures. KKR’s participation broadens the investor base at closing without changing the central feature of the arrangement: Bayer retains majority ownership and operating authority.

The closing announcement also says Apollo originated and led the financing. Apollo Partner Jamshid Ehsani linked the Bayer investment to the firm’s broader capital-deployment plans in Germany, where Apollo says it has committed to deploy more than $100 billion over the coming decade. That figure is a stated Apollo commitment rather than a Bayer-specific funding amount.

The €3 billion strengthens a balance sheet facing heavy cash demands

Bayer’s stated reason for raising the capital has been balance-sheet flexibility. In its July announcement, the company said the financing would strengthen its capital structure while helping it manage higher liquidity requirements in 2026 related to bond maturities and litigation procedures. The company did not say the €3 billion was earmarked exclusively for any one maturity, legal payment or operating program.

The financing has already affected Bayer’s financial outlook. In August, Bayer reduced its expected year-end 2026 net financial debt range to €29 billion to €30 billion, from an earlier forecast of €32 billion to €33 billion. The company explicitly said the change reflected the announced agreement with Apollo-managed funds and affiliates. That guidance was issued before the September closing and therefore anticipated completion of the financing.

The debt context is sizeable relative to the new capital. Bayer ended 2025 with net financial debt of €29.8 billion, down from €32.6 billion a year earlier. By the end of the first quarter of 2026, net financial debt had risen to €32.5 billion, mainly because of negative operating cash flow. The €3 billion financing is therefore large enough to have a visible effect on the company’s leverage and liquidity position, but it does not eliminate Bayer’s broader debt burden.

Bayer has also highlighted legal proceedings as a source of possible liquidity pressure. Its 2025 annual report says ongoing legal proceedings can create unplanned increases in liquidity requirements, including at short notice. The July financing announcement referred more directly to litigation procedures as one of the reasons the company wanted greater financial flexibility in 2026.

Closing converts the July plan into funded equity capital

The September announcement changes the status of the financing from agreed to completed. When Bayer and Apollo first disclosed the plan on July 10, they expected it to close in the third quarter subject to antitrust approval and customary closing conditions. Apollo now says the €3 billion capital solution has successfully closed, which means the equity funding has moved beyond the signed-agreement stage described in July.

The addition of KKR is the main new structural detail disclosed at closing. Apollo’s July announcement identified Apollo-managed funds and affiliates as the minority investor. The September release says KKR has joined as a significant minority participant alongside Apollo. No public term sheet has been released showing the division of economics between Apollo and KKR, and the companies have not disclosed whether KKR joined through a secondary allocation from Apollo or through another arrangement within the financing.

What has not changed is equally important. Bayer still has the majority stake, still controls the LARC operations and has not announced a strategic shift for the business. The financing therefore remains a capital-structure measure built around a core pharmaceuticals asset rather than a divestiture of the LARC business.

The next financial evidence will come through Bayer’s reporting of cash, debt and the new entity after closing. Its existing 2026 guidance already assumes the financing in the lower net-financial-debt range, so future results can show whether the year-end debt outcome remains within that €29 billion to €30 billion band and how the closed investment is reflected in the group’s consolidated accounts.